Published by Josh White on 27th October 2020
(Sharecast News) - Life sciences and technology investor NetScientific announced on Tuesday that its portfolio company PDS Biotechnology has opened the phase 2 clinical trial of 'PDS0101' in combination with standard of care chemoradiotherapy, for the treatment of locally-advanced cervical cancer.